Patient P-03146

Synthetic patientONX-7 · Day 140 · 55–64 · M · baseline S14Open companion preview

Therapy response

Improving

Tolerance

Deteriorating

GI state

Improving

Inflammatory state

Improving

Nutritional resilience

Improving

Discontinuation risk

58%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 ONX-7 started — Baseline state S14
Day 39 NP-02 recommended — Dietary Support Protocol NP-02
Day 40 Patient accepted — Started NP-02 in the companion
Day 50 GI symptom burden −23% vs expected — Dietary Support Protocol NP-02
Day 56 Tolerance state changed — Unstable → Improving
Day 60 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 69 GI-04 recommended — GI Support Protocol GI-04
Day 70 Patient accepted — Started GI-04 in the companion
Day 74 ME-01 recommended — Monitoring Escalation ME-01
Day 75 Patient accepted — Started ME-01 in the companion
Day 78 GI symptom burden −24% vs expected — GI Support Protocol GI-04
Day 78 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
Day 84 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 60.

Primary contributors, last 14 days

GI instability-18
Toxicity+8
Nutritional resilience+7
Inflammatory activity-5
Treatment adherence-4

What helped?

Dietary Support Protocol NP-02Day 39
Result: symptom burden −23%
GI Support Protocol GI-04Day 69
Result: symptom burden −24%
Monitoring Escalation ME-01Day 74
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Dosing / Timing Recommendation DT-01

67%

probability of meaningful tolerance improvement

284 similar trajectories
82% showed improvement
median effect visible after 5 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 31/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↓45
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 49
Mucosal barrier integrity ↓20
- Daily logGI symptom score 47 and rising
Autonomic recovery ↑20
- Wearable3,661 steps/day

DNA

Fictional pharmacogenomic panel

CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2.6 · butyrate capacity 31/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 54 ms
Sleep: 6.2 h
Steps: 3,132
Resting HR: 70 bpm

Daily log: GI score 47, nutritional resilience 42, adherence 55.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-03105	25%	S12	AD-05	no change	60
P-03204	25%	S16	AD-05	improved	48
P-03351	25%	S07	AD-05	no change	51
P-03111	24%	S07	AD-05	no change	48
P-03034	23%	S14	AD-05	no change	30
P-03369	23%	S18	AD-05	no change	37
P-03424	23%	S12	AD-05	improved	41
P-03482	23%	S05	AD-05	no change	67
P-03122	22%	S13	AD-05	no change	40
P-03380	22%	S16	AD-05	improved	34
P-03129	21%	S18	AD-05	no change	32
P-03277	23%	S14	BR-03	improved	41